Drug Therapy

1. Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson's-like symptoms.

Author
Wassef R; Haenold R; Hansel A; Brot N; Heinemann SH; Hoshi T;
Institution
Department of Physiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Journal
J Neurosci. 2007 Nov 21;27(47):12808-16.
Abstract URL
Click here to view abstract

2. Impact of pramipexole on the onset of levodopa-related dyskinesias.

Author
Constantinescu R; Romer M; McDermott MP; Kamp C; Kieburtz K;
Institution
Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA.
Journal
Mov Disord. 2007 May 29;.
Abstract URL
Click here to view abstract

3. Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off.

Author
Deuschl G; Vaitkus A; Fox GC; Roscher T; Schremmer D; Gordin A;
Institution
Department of Neurology, Christian-Albrechts-Universitat, Kiel, Germany.
Journal
Mov Disord. 2007 May 21;.
Abstract URL
Click here to view abstract

4. Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease.

Author
de Bie RM; Miyasaki J; Lang AE; Fox SH;
Institution
Movement Disorders Centre, Division of Neurology University of Toronto, Toronto, Ontario, Canada.
Journal
Can J Neurol Sci. 2007 Nov;34(4):438-42.
Abstract URL
Click here to view abstract

5. Coaxil (tianeptine) in the treatment of depression in Parkinson's disease.

Author
Levin OS;
Institution
Department of Neurology, Russian Medical Academy of Postgraduate Education, Russia.
Journal
Neurosci Behav Physiol. 2007 May;37(4):419-24.
Abstract URL
Click here to view abstract

6. Advances in the Pharmacologic Management of Early Parkinson Disease.

Author
Hauser RA; Zesiewicz TA;
Institution
From the *Department of Neurology and daggerParkinson's Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida; double daggerDepartments of Neurology, Pharmacology and Experimental Therapeutics; and the section signNational Parkinson Foundation Center of Excellence.
Journal
Neurologist. 2007 May;13(3):126-132.
Abstract URL
Click here to view abstract

7. Levodopa raises objective pain threshold in Parkinson's disease: A RIII reflex study.

Author
Gerdelat-Mas A; Simonetta-Moreau M; Thalamas C; Ory-Magne F; Slaoui T; Rascol O; Brefel-Courbon C;
Institution
Hopital Purpan, France.
Journal
J Neurol Neurosurg Psychiatry. 2007 May 15;.
Abstract URL
Click here to view abstract

8. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Author
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G;
Institution
Cardiac Rehabilitation Unit, Istituti Clinici di Perfezionamento, Milan, Italy. cardriab@icp.mi.it
Journal
N Engl J Med. 2007 Jan 4;356(1):39-46.
Abstract URL
Click here to view abstract

9. Rivastigmine and Parkinson dementia complex.

Author
Moretti R; Torre P; Vilotti C; Antonello RM; Pizzolato G;
Institution
University of Trieste, Clinical Neurology, Department of Internal Medicine and Clinical Neurology, Ospedale di Cattinara, Strada di Fiume, 447 34149 Trieste, Italy. moretti@univ.trieste.it
Journal
Expert Opin Pharmacother. 2007 Apr;8(6):817-29.
Abstract URL
Click here to view abstract

10. When Should Levodopa Therapy be Initiated in Patients with Parkinson's Disease?

Author
Halkias IA; Haq I; Huang Z; Fernandez HH;
Institution
Department of Neurology, University of Florida, Gainesville, Florida, USA.
Journal
Drugs Aging. 2007;24(4):261-73.
Abstract URL
Click here to view abstract

11. Dopamine agonists and the risk of cardiac-valve regurgitation.

Author
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E;
Institution
Department of Clinical Pharmacology, Charite Campus Mitte, Charite-Universitatsmedizin Berlin, Berlin.
Journal
N Engl J Med. 2007 Jan 4;356(1):29-38.
Abstract URL
Click here to view abstract